Neurobo Pharmaceuticals Inc. has entered into licensing agreement with Dong-A ST Co Ltd. to develop and commercialize its herbal drug candidate DA-9801 for diabetic neuropathy. Under the agreement, Dong-A ST will received upfront payment of USD 2 million and a 5% stake in NeuroBo Pharma. In addition, NeuroBo Pharma agreed to pay Dong-A ST up to USD 178 million milestone payments and additional sales-tied royalties if the drug candidate clears clinical and commercial milestones. DA-9801 is a treatment for diabetic neuropathy. In 2011, the drug received support from the Ministry of Health and Welfare's healthcare research and development project.